Minimal/JJ
residual/JJ
disease/NN
in/IN
acute/JJ
myelogenous/JJ
leukemia/NN
with/IN
PML/RAR/NN
alpha/NN
or/CC
AML1/ETO/NN
mRNA/NN
and/CC
phenotypic/JJ
analysis/NN
of/IN
possible/JJ
T/NN
and/CC
natural/JJ
killer/NN
cells/NNS
in/IN
bone/NN
marrow/NN
./.

Here/RB
we/PRP
studied/VBN
minimal/JJ
residual/JJ
disease/NN
(/(
MRD/NN
)/)
of/IN
patients/NNS
with/IN
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
who/WP
have/VBP
PML/RAR/NN
alpha/NN
or/CC
AML1/ETO/NN
as/RB
well/RB
as/IN
the/DT
phenotypic/JJ
analysis/NN
of/IN
lymphocyte/NN
subsets/NNS
involved/VBN
in/IN
antitumor/NN
immunity/NN
./.
=====
Eight/CD
patients/NNS
in/IN
long-term/JJ
(/(
LT/JJ
;/:
3/CD
to/TO
15/CD
years/NNS
)/)
and/CC
15/CD
patients/NNS
in/IN
short-term/JJ
(/(
ST/JJ
;/:
up/RB
to/TO
3/CD
years/NN
)/)
remission/NN
were/VBD
studied/VBN
./.
=====
Using/VBG
the/DT
reverse/JJ
transcription-polymerase/NN
chain/NN
reaction/NN
(/(
RT/NN
)/)
assay/NN
,/,
the/DT
limit/NN
of/IN
detection/NN
was/VBD
10(-5)/CD
to/TO
10(-6)/CD
for/IN
PML/RAR/NN
alpha/NN
transcript/NN
and/CC
10(-4)/CD
to/TO
10(-5)/CD
for/IN
the/DT
AML1/ETO/NN
transcript/NN
./.
=====
Simultaneously/RB
,/,
T/NN
lymphocyte/NN
subsets/NNS
and/CC
NK/NN
cells/NNS
from/IN
the/DT
peripheral/JJ
blood/NN
(/(
PB/NN
)/)
and/CC
bone/NN
marrow/NN
(/(
BM/NN
)/)
were/VBD
investigated/VBN
by/IN
flow/NN
cytometric/JJ
analysis/NN
./.
=====
Four/CD
of/IN
the/DT
eight/CD
patients/NNS
in/IN
LT/JJ
and/CC
7/CD
of/IN
the/DT
15/CD
patients/NNS
in/IN
ST/JJ
remission/NN
were/VBD
MRD-positive/JJ
./.
=====
Although/IN
all/DT
MRD-positive/JJ
patients/NNS
in/IN
LT/JJ
remission/NN
are/VBP
still/RB
until/IN
now/RB
event-free/RB
,/,
3/CD
of/IN
the/DT
7/CD
MRD-positive/JJ
(/(
MRD+/JJ
)/)
patients/NNS
in/IN
ST/JJ
remission/NN
soon/IN
relapsed/NN
./.
=====
The/DT
total/JJ
populations/NNS
of/IN
CD4+/JJ
,/,
CD8+/JJ
and/CC
CD56+/JJ
[/(
possible/JJ
T-cell/NN
and/CC
natural/JJ
killer/NN
(/(
T/NK/NN
)/)
populations/NNS
]/)
in/IN
the/DT
BM/NN
of/IN
ST/JJ
patients/NNS
and/CC
MRD+/LT/JJ
patients/NNS
were/VBD
significantly/RB
(/(
p/NN
</JJR
.01/CD
)/)
low/JJ
./.
=====
The/DT
CD8+/JJ
CD28+/JJ
population/NN
showed/VBD
the/DT
same/JJ
tendency/NN
(/(
p/NN
</JJR
.01-.02/CD
)/)
./.
=====
The/DT
T/NK/NN
subsets/NNS
in/IN
the/DT
BM/NN
of/IN
MRD-negative/JJ
(/(
MRD-/JJ
)/)
LT/JJ
(/(
MRD-/LT/JJ
)/)
patients/NNS
showed/VBD
similar/JJ
numbers/NNS
of/IN
cells/NNS
as/IN
normal/JJ
volunteers/NNS
./.
=====
Basically/RB
,/,
the/DT
total/JJ
percentage/NN
of/IN
the/DT
CD4+/JJ
,/,
CD8+/JJ
and/CC
CD56+/JJ
cell/NN
populations/NNS
in/IN
the/DT
BM/NN
was/VBD
increased/VBN
and/CC
in/IN
the/DT
following/VBG
order/NN
:/:
MRD-/LT/JJ
patients/NNS
,/,
normal/JJ
volunteers/NNS
,/,
MRD+/LT/JJ
patients/NNS
and/CC
MRD+/JJ
or/CC
-/ST/JJ
patients/NNS
./.
=====
The/DT
percentages/NNS
of/IN
the/DT
T/NK-cell/NN
subsets/NNS
in/IN
the/DT
PB/NN
were/VBD
not/RB
significantly/RB
different/JJ
among/IN
these/DT
groups/NNS
./.
=====
Thus/RB
,/,
the/DT
difference/NN
of/IN
the/DT
possible/JJ
T/NK-cell/JJ
phenotype/NN
in/IN
the/DT
BM/NN
may/MD
strongly/RB
influence/VB
clinical/JJ
and/CC
molecular/JJ
remission/NN
./.
=====
These/DT
results/NNS
still/RB
remain/VBP
to/TO
be/VB
confirmed/VBN
by/IN
further/JJ
studies/NNS
of/IN
the/DT
functional/JJ
anti-tumor/JJ
immunity/NN
of/IN
T/NK/NN
cells/NNS
of/IN
AML/NN
in/IN
remission/NN
./.